SARCLISA + Pd (ICARIA-MM): TRIAL RESULTS
SARCLISA + Pd extended median progression free survival by 5 months vs. Pd alone1
PROGRESSION-FREE SURVIVAL
SARCLISA + Pd extended mPFS by 5 months vs. Pd alone1
5 month increase in mPFS vs. Pd alone

Adapted from Attal M et al. 2019.1
40%reduction in risk of progression or death in patients receiving SARCLISA + Pd vs. Pd alone
(11.53 vs. 6.47 months [absolute change 5 months]; HR 0.596 [95% CI: 0.44, 0.81; p=0.001])1
- With a median duration of follow-up of 11.6 months, median OS was not reached for either treatment group at the time of analysis. The HR for OS was 0.60 (95% CI: 0.46, 1.02; p=0.0631).1
OVERALL RESPONSE RATE
SARCLISA + Pd demonstrated superior response rates vs. Pd alone1
3.56x increase in ≥VGPR with SARCLISA + Pd vs. Pd alone (32% vs. 9%; p<0.0001)1

Adapted from Attal M et al. 2019.1
Patients responded more quickly with SARCLISA + Pd vs. Pd alone1

SUBGROUP ANALYSES
A PFS benefit vs. Pd alone that was consistent
across pre‑specified patient subgroups
…including those with poor prognosis*
Adapted from Attal M et al. 2019.1